Rezafungin: an opportunity to personalize the treatment of patients with candidemia. [PDF]
Crit CareHonore PM, Cornely OA, Soriano A.
europepmc +4 more sources
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin [PDF]
Drugs, 2021 The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture.
M. Hoenigl +11 more
semanticscholar +5 more sources
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
Microbiology Spectrum, 2023 Rezafungin is a novel once-weekly echinocandin for intravenous injection currently in development for the treatment of Candida infections and the prevention of Candida, Aspergillus, and Pneumocystis infections in allogeneic blood and marrow transplant ...
Shawn Flanagan +3 more
doaj +3 more sources
Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany. [PDF]
Open Forum Infect DisOutcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program.
Trapani F +6 more
europepmc +2 more sources
IDCasesIntroduction: Invasive candidiasis is a common healthcare-associated infection with significant morbidity and mortality. Candida auris in particular has emerged as a problematic and challenging healthcare-associated infection, especially with regards to ...
Matthew A. Stack +5 more
doaj +2 more sources
Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy [PDF]
Pharmacology Research & Perspectives, 2019 Rezafungin acetate is a novel echinocandin in clinical development for prevention and treatment of invasive fungal infections. Rezafungin is differentiated by a pharmacokinetic/pharmacodynamic (PK/PD) profile that includes a long half‐life allowing once ...
Lynn Miesel, Kun‐Yuan Lin, Voon Ong
doaj +3 more sources
Successful outpatient parenteral antimicrobial therapy with rezafungin for chronic pulmonary aspergillosis: a case report and health economic assessment. [PDF]
JAC Antimicrob ResistBackground Chronic pulmonary aspergillosis (CPA) is a serious lung disorder caused by Aspergillus fungal infection with high morbidity and mortality. Treatment options include antifungal azoles, polyenes and echinocandins.
Law SM +5 more
europepmc +2 more sources
Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data [PDF]
Journal of Fungi, 2020 Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique ...
Yanan Zhao, David S. Perlin
doaj +3 more sources
Rezafungin: A Review in Invasive Candidiasis
DrugsRezafungin (Rezzayo®) is a next-generation echinocandin antifungal with improved pharmacokinetic properties over first-generation echinocandins that allows for once-weekly rather than once-daily intravenous administration.
Simon Fung, M. Shirley
semanticscholar +3 more sources
Efficacy of Rezafungin on <i>Candida albicans</i> Endophthalmitis in a Rabbit Model. [PDF]
Pathog ImmunBackground: Endophthalmitis, a severe infection of the intraocular tissues that can result in permanent loss of vision if not immediately treated, is often caused by fungi, namely Candida albicans.
Saghir J +5 more
europepmc +2 more sources